Abeona Therapeutics Inc (NASDAQ:ABEO) – Research analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Abeona Therapeutics in a report issued on Monday. Jefferies Group analyst M. Raycroft anticipates that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter. Jefferies Group has a “Buy” rating and a $28.00 price objective on the stock. Jefferies Group also issued estimates for Abeona Therapeutics’ Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.90) EPS, FY2019 earnings at ($0.41) EPS, FY2020 earnings at $0.33 EPS and FY2021 earnings at $1.67 EPS.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Abeona Therapeutics had a negative return on equity of 24.57% and a negative net margin of 3,263.92%. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.24 million. The business’s revenue for the quarter was down 16.0% compared to the same quarter last year.
ABEO stock opened at $15.75 on Wednesday. Abeona Therapeutics has a 12 month low of $4.55 and a 12 month high of $22.75. The stock has a market capitalization of $660.00, a PE ratio of -23.86 and a beta of 1.30.
A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp grew its holdings in Abeona Therapeutics by 406.3% in the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 206,775 shares during the period. Vanguard Group Inc. grew its holdings in Abeona Therapeutics by 11.2% in the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after purchasing an additional 108,730 shares during the period. State Street Corp acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $1,900,000. California State Teachers Retirement System acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $275,000. Finally, EAM Investors LLC acquired a new stake in Abeona Therapeutics in the third quarter valued at approximately $2,509,000. Institutional investors own 62.64% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://stocknewstimes.com/2018/03/22/abeona-therapeutics-inc-expected-to-post-q1-2018-earnings-of-0-21-per-share-abeo.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.